Karius

Karius, Inc. operates with the vision of creating a world where infectious diseases are no longer a major threat to human health. By leveraging advanced technologies, Karius focuses on enhancing diagnostic insights crucial for effective treatment. The company's flagship product, the Karius Spectrum®, utilizes cutting-edge clinical metagenomics to perform rapid, non-invasive detection of more than 1,000 pathogens from a single blood sample. This innovative testing method aids healthcare providers in diagnosing life-threatening infections more quickly than traditional methods.

The Karius Spectrum test works by identifying microbial cell-free DNA (mcfDNA) circulating in the bloodstream. This approach allows for the rapid diagnosis of infections that are often difficult to identify through conventional diagnostic tests. By streamlining the testing process, Karius enhances the speed with which clinicians can make informed treatment decisions, ultimately leading to better patient outcomes. Additionally, Karius is committed to continuous improvement and staying at the forefront of technological advancements in genomics and artificial intelligence.